BioAge Labs, Inc. (BIOA) stock
Close on Nov 11, 2026Market cap $269.42MP/E –Yield –
BioAge Labs, Inc. grew revenue 45.3% to $8.60M over the twelve months to Sep 30, 2026. Free cash flow was -$103.00M. At the latest close the market valued the company at $269.42M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $269.42M
- P/E ratio
- –
- Price to sales
- 31.33
- Price to book
- 0.78
- Dividend yield
- –
- Free cash flow yield
- -38.23%
Fundamentals
- Revenue
- $8.60M
- Net income
- -$107.80M
- EPS, diluted
- -$2.55
- Free cash flow
- -$103.00M
- Book value per share
- $7.55
- Diluted shares
- 46M
Trading
- Next earnings
- Mar 23, 2027 (estimated, before the open)
- Previous close
- $5.78
- Open
- $5.83
- Day's range
- $5.75 – $6.08
- Volume
- 436,706
- Average volume (20 days)
- 782,939
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Nov 2025)
- Beta (5 years)
- 1.83
- 52-week range
- $4.81 – $25.95
- RSI (14 days)
- 46.9
- Volatility (1 year)
- 105.5%
- Relative volume
- 0.50×
- WACC
- 14.0%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIOA | S&P 500 | Difference | BIOA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.4% | -2.4% | −5.0 pts | ||
| 3 months | -45.0% | -1.2% | −43.8 pts | ||
| Year to date | -55.6% | +12.3% | −67.9 pts | ||
| 1 year | -25.0% | +12.4% | −37.5 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioAge Labs filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About BioAge Labs
Pharmaceutical Preparations
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for chronic metabolic diseases by targeting human aging biology. The company leverages a proprietary computational platform built on longitudinal human datasets and biobanked samples to identify molecular drivers of longevity and healthspan. Its lead product candidate, BGE-102, is an orally administered, brain-penetrant small-molecule NLRP3 inhibitor under development for cardiometabolic indications, particularly cardiovascular risk reduction in patients with obesity, and ophthalmology indications including diabetic macular edema. BioAge is also advancing apelin receptor agonists for obesity as well as earlier-stage discovery programs in collaboration with major pharmaceutical partners.
Company profile, executives and historyBioAge Labs stock: common questions
What is BioAge Labs's stock price?
BIOA closed at $5.87 on Nov 11, 2026, up 1.56% on the day. Over the past 52 weeks it traded between $4.81 and $25.95.
What is BioAge Labs's market cap?
BioAge Labs was worth $269.42M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BIOA's P/E ratio?
BioAge Labs lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.55), so it has no meaningful P/E ratio.
How much revenue does BioAge Labs make?
BioAge Labs reported revenue of $8.60M for the twelve months to Sep 30, 2026, up 45.3% from a year earlier.
Does BioAge Labs pay a dividend?
No. BioAge Labs has not paid a cash dividend over the last twelve months.
When does BioAge Labs report earnings next?
BioAge Labs is expected to report Q4 FY2026 results on Mar 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BIOA stock performed over the past year?
Including dividends, BIOA returned -25.0% over the past year, against +12.4% for the S&P 500.
How many BIOA shares are sold short?
4M shares were sold short at the latest FINRA report, 10.40% of the float, or 4.3 days of average trading volume.
Who are BioAge Labs's competitors?
Companies most similar to BioAge Labs by business, industry and size include PTN, EVMN, ADAG, RANI, HCWB.
See a number that looks wrong?